Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Etravirine (Intelence®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected, antiretroviral treatment-experienced adults in combination with a boosted protease inhibitor and other antiretroviral medicinal products. Treatment should be initiated by a specialist in accordance with BHIVA guidelines. Etravirine (Intelence®) is not recommended for use as first line therapy. AWMSG is of the opinion that etravirine (Intelence®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | etravirine (Intelence®) | |
| Formulation | 100 mg tablet | |
| Reference number | 140 | |
| Indication | Treatment of human immunodeficiency virus (HIV), in combination with a boosted protease inhibitor and other antiretroviral medicinal products, in antiretroviral treatment-experienced adult patients |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Infections | |
| Assessment type | Full | |
| Status | Recommended | |
| Advice number | 0609 | |
| NMG meeting date | 15/07/2009 | |
| AWMSG meeting date | 12/08/2009 | |
| Ratification by Welsh Government | 11/09/2009 | |
| Date of issue | 15/09/2009 | |